Reported 1 day ago
Viking Therapeutics has gained significant attention for its promising weight loss drug, VK2735, which has shown strong results in clinical trials. Despite its potential to stake a claim in the lucrative weight loss market, the company faces hidden risks from competing drugs developed by industry leaders Eli Lilly and Novo Nordisk, which may soon launch enhanced alternatives. Investors should weigh these risks carefully even as Viking appears poised for growth.
Source: YAHOO